Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
NCT01603095 · View on ClinicalTrials.gov ↗
Study Summary
Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.
Conditions Studied
Study Locations (20)
Other
- The Children's Hospital at Westmead — Westmead
- Osaka University Hospital — Osaka
- Saitama Children's Medical Center — Saitama
- Tokushima University Hospital — Tokushima
- Institut Catala de Traumatologica I Medicina de l'Esport — Barcelona
- Hospital Sant Joan de Deu Barcelona — Barcelona
- Hospital Universitario Virgen de la Victoria — Málaga
- Acibadem University School of Medicine — Istanbul
- Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital — London
- Sheffield Children's NHS Foundation Trust — Sheffield
California
- Harbor-UCLA Medical Center — Los Angeles
- Children's Hospital and Research Center Oakland — Oakland
Delaware
- Nemours/Alfred I. duPont Hospital for Children — Wilmington
Georgia
- Emory University — Decatur
Illinois
- Ann and Robert H Lurie Children's Hospital of Chicago — Chicago
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
Tennessee
- Vanderbilt University — Nashville
Texas
- Baylor College of Medicine — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2012-04 |
| Est. Completion | 2021-02 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603095
The ClinicalTrials.gov registry entry for NCT01603095 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01603095 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Delaware. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01603095 about?
NCT01603095 is a clinical study titled "A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia". Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.
What is the current status of trial NCT01603095?
This trial is currently completed. The enrollment target is 363 participants. The study started on 2012-04. Estimated completion is 2021-02.
What conditions does trial NCT01603095 study?
This clinical trial studies the following conditions: Achondroplasia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01603095?
This trial is sponsored by BioMarin Pharmaceutical, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01603095 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.